Ultimate Fighting Championship athletes will serve as test subjects to find out if the cannabis compound CBD can treat the aches and pains that come hand in hand with their violent sport.

Even though the cannabis business has been around for a very long time, at least in illicit form, investors may forget that marijuana is still a nascent industry. There is no precedent to draw upon of an industrialized country legalizing weed, which means there's been a learning curve for investors, the companies involved, and even Wall Street since Canada allowed the recreational use of marijuana.

Over the past year, a number of Wall Street investment firms have begun throwing their hats in the ring on the cannabis industry, though many have done so cautiously. This past week, Ladenburg Thalmann became the latest Wall Street firm to initiate coverage on the cannabis industry. In total, covering analyst Glenn Mattson started three pot stocks with a buy rating.

Despite being one of Canada’s largest pipeline companies, many investors have not heard of TC Energy (TSX:TRP)(NYSE:TRP) in part due to its name change from TransCanada Corporation earlier this year.

For those of you unacquainted with this company, TC Energy is the driving force behind the infamous Keystone XL pipeline which has faced legal hurdles in the United States.

With President Donald Trump being a staunch supporter of the Keystone XL, the pipeline’s eminent construction will mean huge returns for investors.

The CEO and chairman of Canadian cannabis producer CannTrust(CTST) were told the company was growing unlicensed weed months before regulators discovered the violations, according to a report, further submerging CannTrust stock on Wednesday. Other marijuana stocks were mostly down.

A report from the Globe and Mail said that CEO Peter Aceto and Chairman Eric Paul were informed that CannTrust was growing cannabis in unlicensed rooms at a facility in Ontario.

CannTrust Holdings stock tumbled another 24% Wednesday to drag the overall cannabis sector down, after a report said emails showed the company’s top managers knew that the company was growing unlicensed cannabis at an Ontario facility, months before Health Canada seized tons of its product.

Polly Webb’s pit bull-terrier may be named after one of the fiercer “Game of Thrones” characters, but Drogo proves more of a scaredy cat than a war lord.

“My dog, he’s terrified of thunderstorms,” Webb, a writer and editor from Northeast Baltimore’s Govans neighborhood, said. “Usually, when he’s shaking and afraid, he won’t eat anything.”

To soothe Drogo’s anxieties, she gave him a carob “brownie” infused with CBD (cannabidiol) from Mount Vernon’s The Dog Chef pet store and food shop. She’s one of several local pet owners who consider CBD a viable alternative medicine that alleviates their companions’ aches, pains, and stresses.

It's no secret that marijuana stocks are creating quite a lot of buzz on Wall Street. Over the past couple of years, some of the biggest pot stocks by market cap have delivered quadruple-digit-percentage gains, fueling hope that there are other marijuana stocks that could deliver life-changing long-term gains. And the big sales figures forecast by Wall Street over the next decade certainly suggest additional upside may eventually be warranted.

With cannabis regulations loosening around the world, the industry has been characterized by growth and bullish speculations. Despite the growing acceptance towards cannabis, many investors do not believe all the hype and predict that the industry is overvalued. On July 19, the Investment Industry Regulatory Organization of Canada (IIROC) released its Consolidated Short Position Report, depicting the most shorted cannabis stocks from the period of July 8, 2019 to July 19, 2019. Today, using this report, we have weeded out four of the most-shorted Canadian cannabis stocks in that given period. For reference, a high short ratio is above 10 and one between 1 and 4 shows a positive sentiment and little interest from short sellers (Power Cycle Trading, 2019).

With recreational marijuana dominating public conversation since legalization last October, and even before that, issues with access to medicinal cannabis for Canadians have fallen to the wayside.

That’s according to Dr. Rahim Dhalla, an Ottawa pharmacist who decided to open a pharmacy in Westboro last year that, on top of your standard medications, also offered education and health information surrounding medicinal cannabis and other related products.

Dhalla’s father, a lifelong pharmacist himself, was diagnosed with cancer and saw benefits from cannabidiol (CBD) oils during his treatment, which Dhalla said was the inspiration for the pharmacy.

The cannabis industry has been a bit of a soap opera this month. From Canopy Growth Co-CEO Bruce Linton being let go to CannTrust Holdings (TSX:TRST)(NYSE:CTST) allegedly putting up fake walls and misleading Health Canada about where and how much pot it was growing, there’s been no shortage of headlines recently. The problem is that the negative press has sent pot stocks into a bit of a tailspin and created a lot of instability along the way.